ORG_CITY: PORTLAND

ORG_DEPT: OTHER BASIC SCIENCES

ORG_NAME: OREGON HEALTH & SCIENCE UNIVERSITY

ORG_STATE: OR

PHR: PROJECT NARRATIVE: Overall The overall goal of this ARTNet Center is to understand the biological drivers of acquired drug resistance in acute myeloid leukemia – an aggressive form of leukemia. We will employ novel experimental approaches, advanced models, and a large biorepository of primary samples to study causes of resistance that are intrinsic to the AML tumor cells as well as causes of resistance that are driven by the tumor cells interacting with their local environment. This knowledge will be leveraged to identify and prioritize novel drug combination regimens and translate these new therapeutic strategies into the clinics to prevent drug resistance and improve outcomes for patients with AML.

PI_NAMEs: DRUKER, BRIAN J;MCWEENEY, SHANNON K.;TYNER, JEFFREY WALLACE (contact)

PROGRAM_OFFICER_NAME: SAID, RABIH

PROJECT_TERMS: acquired drug resistance;Acute Myelocytic Leukemia;acute myeloid leukemia cell;Address;anti-tumor immune response;Architecture;Atlases;biobank;Biological;Biological Assay;Biology;Bone Marrow;catalyst;Cell Communication;Cell Line;Cells;Clinic;Clinical;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;Coculture Techniques;cohort;Collaborations;Complement;Complex;Computer Models;CRISPR screen;Data;data integration;Data Set;data sharing;Data Sources;deep sequencing;Deposition;detection method;Development;Disease;Disease remission;Drug Combinations;Drug Exposure;Drug resistance;Drug Sensitization;Engineering;Environment;Epigenetic Process;epigenomics;Evaluation;Evolution;Exhibits;Feedback;functional genomics;Funding;Genetic;genome wide screen;genome-wide;genomic data;Goals;human model;Immune;improved;improved outcome;Intrinsic factor;Knowledge;large datasets;leukemia;Longitudinal Studies;Maps;Mediating;Modeling;monocyte;neoplastic cell;New Drug Approvals;next generation;novel;novel drug combination;novel therapeutic intervention;Outcome;participant enrollment;Pathway interactions;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Phenotype;pressure;prevent;Primary Neoplasm;programs;public repository;Publications;Recurrent disease;Refractory;Refractory Disease;Regimen;relapse prevention;Research Personnel;Resistance;resistance mechanism;Resource Sharing;response;Sampling;Series;Signal Transduction;single cell analysis;Specimen;Standardization;stem cell expansion;Stress;Stromal Cells;Survival Rate;targeted biomarker;targeted treatment;Testing;Therapeutic;therapy resistant;Time;Translating;translational approach;Translations;tumor;tumor-immune system interactions;Work

PROJECT_TITLE: Architecture and Trajectory of Acquired Resistance to Therapy in AML


ADMINISTERING_IC: CA

ARRA_FUNDED: N

FUNDING_MECHANISM: RESEARCH CENTERS

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Cancer;Childhood Leukemia;Hematology;Pediatric;Pediatric Cancer;Rare Diseases

ORG_COUNTRY: UNITED STATES

ORG_FIPS: US

PI_NAMEs: TYNER, JEFFREY WALLACE (contact)

PROJECT_TERMS: acquired drug resistance;Acute Myelocytic Leukemia;Administrator;Agreement;Architecture;Bioinformatics;Biology;Biostatistics Core;Budgets;Clinical;Collaborations;Communication;Communities;Complex;Data;data dissemination;data sharing;Ensure;Environment;Evaluation;Evolution;experience;Fostering;Funding;Goals;Grant;Heme;Individual;innovation;Intellectual Property;Intrinsic factor;Laboratories;Lead;Leadership;leukemia;meetings;National Cancer Institute;novel therapeutic intervention;Office of Administrative Management;operation;Outcome;Patients;Performance;pre-clinical;Preparation;Productivity;programs;Progress Reports;Recommendation;Reporting;Research;Research Personnel;Resistance;Resources;Scientific Evaluation;Scientist;Specimen;System;Technology;therapy resistant;Time;timeline;Translational Research;Travel;tumor;Work

PROJECT_TITLE: Core A: Administrative Core


NIH_SPENDING_CATS: Cancer;Childhood Leukemia;Clinical Research;Data Science;Hematology;Networking and Information Technology R&D (NITRD);Pediatric;Pediatric Cancer;Rare Diseases

PI_NAMEs: VU, TOTHU Q (contact)

PROJECT_TERMS: acquired drug resistance;Acute Myelocytic Leukemia;Address;Architecture;Biological Assay;Biology;cell preparation;Cell Separation;Cell Survival;Clinic;Clinical;Clinical Data;Clinical Trials;Collection;Communication;Communities;Complex;Computerized Medical Record;Consent;Cryopreservation;Data;data acquisition;Data Analyses;Data Correlations;data curation;data integration;data management;Data Scientist;Data Set;data standards;Dedications;Diagnosis;Disease;Disease Progression;Drug Combinations;Ensure;Evolution;Feeds;functional genomics;genomic platform;Goals;Immune signaling;improved;Informed Consent;Infrastructure;Intrinsic factor;large scale data;leukemia;Malignant Neoplasms;Metadata;Methods;Modeling;Molecular;multidisciplinary;neoplastic cell;novel;Patient Isolation;Patient-Focused Outcomes;Patients;Performance;Pharmacotherapy;Phenotype;Preparation;pressure;Procedures;Process;programs;Protocols documentation;quality assurance;Quality Control;Recording of previous events;Research;Research Personnel;Resource Sharing;Resources;Sampling;Security;Signal Transduction;Standardization;Stimulus;Structure;success;System;Therapeutic;therapy resistant;Translational Research;Translations;tumor;tumor microenvironment;Variant;Work

PROJECT_TITLE: Core B: Functional Phenotyping Core


ED_INST_TYPE: SCHOOLS OF MEDICINE

ORG_CITY: ALBUQUERQUE

ORG_DEPT: PATHOLOGY

ORG_NAME: UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR

ORG_STATE: NM

PHR: OVERALL COMPONENT: THE UNIVERSITY OF NEW MEXICO COMPREHENSIVE CANCER CENTER PROJECT NARRATIVE The NCI-Designated University of New Mexico Comprehensive Cancer Center leads impactful cancer research, cancer care delivery, cancer education and training, and community-based cancer prevention and control efforts across the New Mexico catchment area, in partnership with its Consortium Partner (Lovelace Biomedical/The Lovelace Respiratory Research Institute), Tribal Nations, and community health systems statewide. The Center's overall mission is to reduce the cancer burden and overcome the tremendous cancer health disparities of the New Mexico catchment area and the nation through ground-breaking transdisciplinary research, translation of discoveries to clinical and community interventions, impactful bi-directional community engagement, training of a more diverse cancer workforce, and the delivery of exceptional cancer care.

PI_NAMEs: SANCHEZ, YOLANDA  (contact)

PROGRAM_OFFICER_NAME: BELIN, PRECILLA L

PROJECT_TERMS: Advanced Malignant Neoplasm;Advisory Committees;American Indians;anti-cancer research;Behavioral;Black race;Cancer Biology;Cancer Burden;cancer care;Cancer Center;Cancer Center Support Grant;cancer clinical trial;Cancer Control;Cancer Control Research;cancer education;cancer health disparity;cancer prevention;cancer research center director;care delivery;career;career development;Catchment Area;cellular oncology;Characteristics;Clinic;Clinical;clinical care;Clinical Trials Network;Collaborations;Communities;Community Clinical Oncology Program;community engagement;Community Health;Community Health Systems;community intervention;Community Outreach;community setting;Comprehensive Cancer Center;Data;data modeling;Development Plans;Disparity;Doctor of Philosophy;Education;education access;Educational Activities;Environment;environment related cancer;Environmental Exposure;ethnic diversity;Ethnic Population;Etiology;Evaluation;Event;Extramural Activities;Faculty;Fellowship;Fellowship Program;Fostering;Foundations;Funding;gender diversity;Genetic;Genomic medicine;Goals;Grant;Grant Review;hackathon;Health;health equity;Health system;High School Student;Hispanic;hispanic community;HPV screening;improved;Incidence;Individual;Informatics;Infrastructure;Institution;Institutional support resources;Instruction;inter-institutional;Interdisciplinary Study;Intervention;K-Series Research Career Programs;Laboratories;Latino;Leadership;lectures;Logic;Malignant Neoplasms;meetings;member;Mentors;Mentorship;Mexican;Minority;Mission;Modeling;molecular oncology;mortality;multi-ethnic;NCI Center for Cancer Research;New Mexico;Not Hispanic or Latino;novel;Oncology;Outcome Measure;Pattern;Persons;Population;population based;Population Sciences;predictive modeling;programs;Provider;Public Health;Publications;racial diversity;Registries;Research;Research Institute;Research Personnel;Resource Sharing;Resources;respiratory;role model;Rural;Science;Scientist;screening;SEER Program;Series;skill acquisition;skills;social;socioeconomics;Source;Strategic Planning;Structure;Students;Surveys;Technology;Therapeutic;Training;Training and Education;Training Programs;Training Support;Translating;translational cancer research;Translational Research;Translations;Travel;tribal Nation;Trust;tumor registry;Underrepresented Minority;Universities;Visualization;Woman

PROJECT_TITLE: University of New Mexico Cancer Center Support Grant

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Cancer Centers Study Section (A)[NCI-A]


ADMINISTERING_IC: MH

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL INSTITUTE OF MENTAL HEALTH

NIH_SPENDING_CATS: Behavioral and Social Science;Brain Disorders;Clinical Research;Depression;Dissemination and Implementation Research;HIV/AIDS;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Infectious Diseases;Mental Health;Networking and Information Technology R&D (NITRD);Prevention;Rural Health;Social Determinants of Health;Substance Misuse;Telehealth

ORG_CITY: BIRMINGHAM

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: UNIVERSITY OF ALABAMA AT BIRMINGHAM

ORG_STATE: AL

PHR: Narrative Depression and substance use disorders (SUD) in persons living with HIV (PLWH), when untreated, threaten HIV care continuum outcomes such as engagement in care and treatment adherence. HIV, mental health (MH), and SUD, disproportionately affect rural and Southern states due to proximity to medical care and a lack of mental health and addiction providers. Through enhanced screening (patient-reported outcomes) and linkage to expanded treatment options (telemedicine), this proposal will optimize care of depression and SUD, a critical step towards ending the HIV Epidemic.

PI_NAMEs: EATON, ELLEN FLORENCE (contact)

PROGRAM_OFFICER_NAME: SENN, THERESA ELAINE

PROJECT_TERMS: Acceleration;accurate diagnosis;addiction;Address;Adherence;Affect;Alabama;Annual Reports;Anti-Retroviral Agents;Behavioral Model;Caring;Characteristics;Client;Clinic;clinic ready;Clinical;Communities;comorbidity;Consolidated Framework for Implementation Research;Continuity of Patient Care;Data;Diagnosis;Diagnostic;diagnostic accuracy;Documentation;Effectiveness;effectiveness evaluation;Enabling Factors;Epidemic;experience;Face;Funding;Health;Health behavior;health care service utilization;Health Personnel;Health Services Research;HIV;HIV/AIDS;hybrid type 1 design;implementation evaluation;implementation outcomes;implementation science;implementation strategy;improved;Individual;information gathering;innovative technologies;Intervention;intervention effect;Knowledge;Maintenance;Measures;Medicaid;Medical;medical specialties;Mental Depression;Mental Health;Mental Health Services;Monitor;multi-component intervention;Needs Assessment;novel;Outcome;patient level intervention;Patient Outcomes Assessments;Patient-Focused Outcomes;Patients;Penetrance;Persons;Population;Poverty Areas;Predisposing Factor;Prevention;programs;Provider;psychosocial;Reporting;Research;Research Design;Research Personnel;Resources;routine care;Rural;rural area;rurality;scale up;screening;Screening procedure;service delivery;Services;Site;Standardization;Stretching;Substance Use Disorder;Telemedicine;Testing;Time;tool;Training;treatment adherence;United States Health Resources and Services Administration;Universities;uptake;Viral;Viral Load result;Visit;Vulnerable Populations

PROJECT_TITLE: HIV+ Service delivery and Telemedicine through Effective PROs


NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Childhood Leukemia;Clinical Research;Genetics;Hematology;Human Genome;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human

PROJECT_TERMS: acquired drug resistance;Acute Myelocytic Leukemia;acute myeloid leukemia cell;Architecture;Atlases;Automobile Driving;BCL2 gene;Biological;Biology;Bone Marrow;Bypass;CD34 gene;Cell Line;Cells;Clinic;Clinical;clinical translation;Clinical Trials;clinically relevant;Clonal Evolution;Clustered Regularly Interspaced Short Palindromic Repeats;cohort;Combined Modality Therapy;Complex;computer framework;CRISPR interference;CRISPR screen;cytokine;Data;data integration;data modeling;Data Set;Disease;Disease remission;Drug Combinations;Drug Exposure;Drug resistance;drug response prediction;drug sensitivity;Epigenetic Process;epigenomic profiling;epigenomics;Event;Evolution;Exhibits;Expression Profiling;FLT3 inhibitor;functional genomics;Gene Expression;Gene Expression Profiling;Genes;genome-wide;genomic data;genomic platform;Goals;Hematologic Neoplasms;Immune;improved;Inferior;innovation;insight;Intrinsic factor;knock-down;knockout gene;Lead;leukemic stem cell;Maps;Mediating;Modeling;models and simulation;Mutation;Myeloid Progenitor Cells;neoplastic cell;next generation;novel;novel therapeutics;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;pressure;prevent;Primary Neoplasm;Process;Protocols documentation;Recurrent disease;Refractory;Refractory Disease;Regimen;Relapse;Resistance;resistance mechanism;response;Rest;Salvage Therapy;Sampling;Signal Transduction;single cell analysis;single cell sequencing;stem cells;Stromal Cells;Supporting Cell;Techniques;Technology;Testing;Therapeutic;Therapeutic Intervention;therapy resistant;Translating;treatment response;tumor;Work

PROJECT_TITLE: Trajectory and Architecture of Tumor Intrinsic Drug Resistance in AML


NIH_SPENDING_CATS: Cancer;Ovarian Cancer;Rare Diseases;Women's Health Research

ORG_CITY: ROCHESTER

ORG_NAME: MAYO CLINIC ROCHESTER

ORG_STATE: MN

PHR: NARRATIVE– DEVELOPMENTAL RESEARCH PROGRAM (DRP) The Developmental Research Program supports young investigators or those new to ovarian cancer research, with the goal of identifying promising pilot studies. The objective of these preliminary studies is to generate new ideas that could be tested in larger projects or in clinical trials for ovarian cancer patients.

PI_NAMEs: CLIBY, WILLIAM A (contact)

PROJECT_TERMS: Advisory Committees;anti-cancer research;Award;base;Cancer Patient;Chicago;Clinic;Clinical Investigator;Clinical Research;Clinical Trials;clinically relevant;Collaborations;Communities;Creativeness;Data;Development;Direct Costs;Disabled Persons;Disease;experience;Extramural Activities;Facilities and Administrative Costs;Fostering;Funding;Goals;Grant;Human Resources;improved;Individual;innovation;Institution;interdisciplinary collaboration;interest;Intervention;Laboratory Study;Letters;Malignant neoplasm of ovary;Mayo Clinic Cancer Center;Measures;Minnesota;Minority;Monitor;originality;Ovarian;Patient advocacy;Patients;Peer Review;Pilot Projects;Policies;Population;Population Study;Process;Program Research Project Grants;programs;Publications;Qualifying;Recommendation;Research;research and development;Research Personnel;Research Project Grants;Research Support;sound;Stimulus;success;System;Testing;timeline;Translating;translational goal;translational pipeline;translational potential;Translational Research;United States National Institutes of Health;Universities;Woman;Work

PROJECT_TITLE: Development Research Program


ORG_CITY: LOS ANGELES

ORG_NAME: CEDARS-SINAI MEDICAL CENTER

ORG_STATE: CA

PHR: PROJECT NARRATIVE (PROJECT 4) The overall goal of Project 4 is to understand the relationship between expression and activation of the master regulator transcription factor ONECUT2 (OC2), lineage plasticity, chromosome instability and nuclear shape instability. We have found these to be shared features of both treatment-naïve de novo metastatic prostate cancer (PC) and metastatic castration-resistant PC, suggesting these properties are inherent to one or more subtypes of aggressive PC. We will use model systems, human data and tissues, and a range of molecular and computational approaches to identify new therapeutic approaches to lethal forms of PC. Project Narrative Page 700

PI_NAMEs: FREEMAN, MICHAEL R (contact);GARRAWAY, ISLA PEARL

PROGRAM_OFFICER_NAME: AULT, GRACE S

PROJECT_TERMS: 3-Dimensional;androgen independent prostate cancer;Androgen Receptor;Aneuploidy;Bioinformatics;Biological Assay;Biological Models;Bone Marrow;Breast Cancer Cell;Bulla;Castration;Cell Separation;Cessation of life;Chromosomal Instability;chromosome missegregation;Clonal Expansion;cohort;Cytoplasm;Diagnostic;Disease;Down-Regulation;drug-like compound;emerin;Epithelium;Exhibits;Expression Profiling;extracellular vesicles;Family;Funding;Genes;Genetic Transcription;Genetically Engineered Mouse;Genome;genomic data;Genomic Instability;Goals;Growth;Histologic;Histology;Human;human data;human model;human tissue;Hypoxia;in vivo;inhibitor;inhibitor therapy;Longterm Follow-up;Malignant neoplasm of prostate;Membrane Proteins;men;Mesenchymal;Metastatic Prostate Cancer;Methods;micronucleus;Molecular;Mus;Needle biopsy procedure;Neoplasm Circulating Cells;Neoplasm Metastasis;neoplastic cell;Neurosecretory Systems;Newly Diagnosed;novel;novel marker;novel therapeutic intervention;Nuclear;Nuclear Envelope;Nuclear Inner Membrane;Patients;Phenotype;Ploidies;Population;pressure;Primary Neoplasm;Process;prognostic;programs;Property;Prostate;prostate cancer cell;prostate cancer metastasis;Prostatic Neoplasms;Receptor Signaling;regeneration model;Reporting;Resistance;Role;Shapes;Signal Transduction;single cell analysis;small molecule;Specific qualifier value;stemness;Stimulus;Tissue Grafts;tissue regeneration;Tissues;transcription factor;tumor growth;tumor heterogeneity;Variant;Xenograft procedure

PROJECT_TITLE: Mechanisms of Prostate Cancer Metastasis


NIH_SPENDING_CATS: Cancer;Cancer Genomics;Childhood Leukemia;Clinical Research;Genetics;Hematology;Human Genome;Orphan Drug;Pediatric;Pediatric Cancer;Precision Medicine;Rare Diseases

PI_NAMEs: AGARWAL, ANUPRIYA  (contact)

PROJECT_TERMS: acquired drug resistance;Acute Myelocytic Leukemia;acute myeloid leukemia cell;Aftercare;Architecture;ATAC-seq;BCL2 gene;Biology;Bone Marrow;cancer cell;Cell Line;Cell Survival;Cells;Clinical;Clustered Regularly Interspaced Short Palindromic Repeats;Coculture Techniques;Combined Modality Therapy;Communication;Complex;CRISPR screen;cytokine;Data;data integration;Data Set;deep sequencing;Development;disorder control;DNA sequencing;Drug Combinations;Drug Modulation;Drug resistance;drug resistance development;drug sensitivity;Drug Sensitization;Engineering;Environment;Epigenetic Process;Event;Evolution;Exposure to;FGF2 gene;Flow Cytometry;FLT3 gene;FLT3 inhibitor;Funding;Gene Expression;Genetic;Genetic Heterogeneity;genome-wide;Goals;Growth;Growth Factor;Heterogeneity;Immune;Immune Evasion;Immune signaling;Immune Targeting;Immunofluorescence Immunologic;Immunologic Factors;immunoregulation;improved;Inflammatory;inhibitor;Interleukin-1;JAK2 gene;leukemia;Leukemic Cell;leukemic stem cell;Malignant - descriptor;Maps;Mediating;MEKs;Methylation;Modeling;Molecular;monocyte;Multiomic Data;Mutation;Natural Killer Cells;neoplastic cell;network models;new combination therapies;novel;novel therapeutic intervention;Organoids;Outcome;Pathway interactions;Patients;Pharmaceutical Preparations;Pharmacotherapy;Play;predictive modeling;Process;Proteomics;Recurrent disease;Refractory;Refractory Disease;Relapse;Residual state;Resistance;resistance mechanism;response;Role;Route;Sampling;screening;Screening Result;Shapes;Signal Pathway;Signal Transduction;single-cell RNA sequencing;small molecule inhibitor;Stress;Stromal Cells;T-Lymphocyte;targeted treatment;Testing;Therapeutic;Therapeutic Intervention;therapeutic target;therapy resistant;transcriptome sequencing;transcriptomics;translational impact;treatment response;tumor;tumor microenvironment

PROJECT_TITLE: Trajectory and Architecture of Microenvironment-Mediated Resistance in AML


ED_INST_TYPE: HOSPITALS

NIH_SPENDING_CATS: Cancer;Lung;Lung Cancer

ORG_CITY: HOUSTON

ORG_NAME: UNIVERSITY OF TX MD ANDERSON CAN CTR

ORG_STATE: TX

PHR: Project Narrative The identification of targetable driver oncogenes, such as EGFR, has been a revolutionary advancement in the treatment of lung cancer, and inhibitors can cause dramatic reductions in tumor bulk markedly improving clinical outcomes for patients. However, these drugs do not completely eradicate tumors leaving residual cells that are not killed by the initial treatment, called drug-tolerant persister cells (DTPCs) which eventually resume growth and metastatic spread. To tackle this, we aim to characterize at the single cell level a large and valuable collection of EGFR mutant DPTCs and drug resistant preclinical models that were established in order to investigate new therapeutic approaches for the early targeting of DTPCs to prevent resistant disease.

PI_NAMEs: NILSSON, MONIQUE B (contact)

PROGRAM_OFFICER_NAME: FORRY, SUZANNE L

PROJECT_TERMS: aurora kinase;Cells;Clinic;Clinical;Clinical Trials;Collection;Critical Pathways;Dependence;Development;Disease Resistance;Drug resistance;Drug Targeting;Drug Tolerance;Epidermal Growth Factor Receptor;Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor;FOXM1 gene;Genetic;Goals;Growth;Hormones;improved;inhibitor;Institution;Interleukin-6;Laboratories;Laboratory Research;Lung;Lung Neoplasms;Malignant neoplasm of lung;Malignant Neoplasms;Molecular;mutant;Non-Small-Cell Lung Carcinoma;novel;novel therapeutic intervention;novel therapeutics;Oncogenes;Patient-Focused Outcomes;Pharmaceutical Preparations;pre-clinical;Pre-Clinical Model;prevent;Residual state;Resistance;resistance mechanism;Signal Pathway;Solid Neoplasm;Stress;Therapeutic;Time;Translating;treatment strategy;tumor;tumor eradication;Tyrosine Kinase Inhibitor;Vascular Endothelial Growth Factors

PROJECT_TITLE: Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)


NIH_SPENDING_CATS: Bioengineering;Cancer;Cancer Genomics;Childhood Leukemia;Clinical Research;Genetics;Hematology;Human Genome;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

PI_NAMEs: DRUKER, BRIAN J (contact)

PROJECT_TERMS: 3-Dimensional;acquired drug resistance;Acute Myelocytic Leukemia;acute myeloid leukemia cell;Architecture;ATAC-seq;Automobile Driving;BCL2 gene;Biological Assay;Biological Markers;Blood Vessels;bone engineering;Bone Marrow;Cell Communication;Cell Differentiation process;Cell Line;Cell model;Cells;Clinical;clinical translation;Clinical Trials;Clonal Evolution;Collaborations;Combination Drug Therapy;Combined Modality Therapy;Complex;Correlative Study;Data;deep sequencing;Detection;detection method;Development;Disease;Drug Combinations;Drug resistance;drug testing;Early Diagnosis;Epigenetic Process;Evaluation;Evolution;Flow Cytometry;FLT3 gene;Future;Gene Expression;Goals;high throughput screening;Human;Human Resources;Image;Immune;Immunosuppression;Immunotherapy;improved;inhibitor;Institution;Intervention;leukemia;Leukemic Cell;longitudinal analysis;Measures;Metabolic;metabolomics;Methodology;Methods;Modeling;Mutation;mutational status;Natural Killer Cells;neoplastic cell;Newly Diagnosed;novel;novel drug combination;novel therapeutics;operation;Outcome;participant enrollment;Pathway interactions;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Phenotype;predictive signature;prevent;Process;Proteins;Recurrent disease;Regimen;Relapse;Research Personnel;Resistance;Resistance development;resistance mechanism;resistance mutation;response;Sampling;Signal Transduction;single cell analysis;single-cell RNA sequencing;small molecule;Specimen;Stromal Cells;T-Lymphocyte;targeted treatment;Techniques;Technology;Testing;Therapeutic;Therapy Clinical Trials;therapy resistant;three-dimensional modeling;Time;Transcript;Translating;translational potential;Translations;tumor;Validation;Work

PROJECT_TITLE: Translating Improved Pairing and Timing of Drug Combination Strategies


PHR: NARRATIVE – CAREER ENHANCEMENT PROGRAM (CEP) The Career Enhancement Program seeks to identify and mentor new and developing investigators in ovarian cancer research. The SPORE assists these individuals by providing mentoring teams, actively integrating the awardee into the SPORE, and providing access to Core resources while encouraging each awardee to generate sufficient data and a trajectory toward independent funding in ovarian cancer research.

PI_NAMEs: COUCH, FERGUS JOSEPH (contact)

PROJECT_TERMS: Achievement;Advisory Committees;Animal Model;anti-cancer research;Applications Grants;Area;Award;base;Basic Science;Bioinformatics;Biometry;Cancer Center;Cancer Research Project;candidate selection;career;career development;Clinic;Clinical Sciences;Communities;Data;Development;Diagnosis;Disabled Persons;Disease;diversity and inclusion;Eligibility Determination;Ensure;Environment;expectation;Extramural Activities;Faculty;Funding;Future;Goals;Grant;improved;Individual;interest;Leadership;Malignant neoplasm of ovary;Manuscripts;Mayo Clinic Cancer Center;Medicine;meetings;Mentors;Mentorship;Minority;Monitor;multidisciplinary;Ovarian;Patient advocacy;patient registry;Peer Review;Policies;Population Sciences;Prevention;Procedures;Process;Productivity;programs;Published Comment;Publishing;Qualifying;recruit;Reporting;Research;Research Personnel;Resources;Role;Scientist;Secure;Series;skills;success;System;Translational Research;translational scientist;Woman;women's treatment;Work;Writing

PROJECT_TITLE: Career Enhancement Program


NIH_SPENDING_CATS: Cancer

PROJECT_TERMS: Advisory Committees;anti-cancer research;Applications Grants;Award;Basic Science;Budgets;cancer care;Cancer Center;Cancer Center Support Grant;cancer prevention;cancer research center director;cancer therapy;Cities;Clinical Research;Clinical Sciences;Clinical Trials;Clinical Trials Network;Collaborations;Communication;community advisory board;community engagement;Community Health Education;Community Outreach;community partners;County;Data;Databases;Development;Development Plans;Direct Costs;Educational workshop;Electronics;Ensure;Evaluation;Event;Expenditure;Extramural Activities;Faculty;Fostering;Funding;Funding Agency;Funding Opportunities;Grant;Growth;Health;Health Sciences;innovation;Institution;interdisciplinary collaboration;Laboratories;Leadership;Malignant Neoplasms;medical schools;meetings;member;Mexican;Mission;Monitor;National Cancer Institute;NCI Center for Cancer Research;New Mexico;Nursing Faculty;Office Management;operation;Operations Research;Outcome;Philanthropic Fund;Physicians;Pilot Projects;Play;Preparation;Process;programs;Progress Reports;Publications;recruit;Reporting;Research;Research Infrastructure;Research Institute;Resource Sharing;respiratory;Role;Scheduling and Staffing;Science;Scientist;Series;Strategic Planning;Strategic vision;System;tool;Training;Training and Education;training opportunity;Universities

PROJECT_TITLE: Cancer Center Administration


ADMINISTERING_IC: DE

ED_INST_TYPE: SCHOOLS OF DENTISTRY/ORAL HYGN

IC_NAME: NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH

NIH_SPENDING_CATS: Clinical Research;Dental, Oral, and Craniofacial Disease;Infectious Diseases;Microbiome

ORG_CITY: Newark

ORG_DEPT: DENTISTRY

ORG_NAME: RUTGERS BIOMEDICAL AND HEALTH SCIENCES

ORG_STATE: NJ

PHR: Public Health Relevance Current antibacterial treatment strategies for peri-implantitis lack efficacy in resolving the destructive inflammation that causes loss of jawbone, which necessitates the comprehensive study of microbial biofilm pathogenicity around implants. This study aims to understand the role of V. parvula in the polymicrobial shift that takes place in the pathogenesis of Titanium-mediated peri-implantitis by focusing upon its ability to cross- protect pathogenic bacteria from oxidative environmental stress.

PI_NAMEs: KOTSAKIS, GEORGIOS  (contact)

PROGRAM_OFFICER_NAME: MCNEALY, TAMARA L

PROJECT_TERMS: Address;Affect;Anti-Bacterial Agents;Antibiotic Therapy;antimicrobial;antioxidant enzyme;Antioxidants;Bacteria;Biodiversity;Biological Models;Biomass;bone loss;catalase;Cell Death;Characteristics;Clinical;commensal bacteria;Communities;Complex;Coupled;cross immunity;Data;Dental;Dental Implants;Disease;Drug Metabolic Detoxication;dysbiosis;Ecology;Enzymes;Excision;Exhibits;Fusobacterium nucleatum;Genes;Genetic;Genetic Transcription;Goals;Growth;gut dysbiosis;Health;health related quality of life;Homeostasis;Human;human data;Hygiene;Immunologic Surveillance;Impairment;Implant;in vivo;Infection;Inflammation;Inflammatory;insight;Investigation;Knowledge;Lytic;Mechanics;Mediating;Methodology;microbial;Microbial Biofilms;microbial community;microbiome;microbiome composition;microorganism;Modeling;Morbidity - disease rate;mutualism;new therapeutic target;opportunistic pathogen;oral biofilm;oral commensal;Oral health;Oral mucous membrane structure;oral pathogen;Orthopedics;oxidative damage;Oxidative Stress;Oxidative Stress Induction;Oxygen;particle;pathogen;Pathogenesis;pathogenic bacteria;Pathogenicity;Patients;peri-implantitis;Periodontitis;Phase;Porphyromonas gingivalis;Public Health;public health relevance;Reactive Oxygen Species;Relapse;Research;resident commensals;Respiratory Burst;response;Role;Side;Signal Pathway;soft tissue;Stress;synergism;System;Testing;Therapeutic;Titanium;transcriptomics;treatment strategy;Up-Regulation;Veillonella;Veillonella parvula;Work

PROJECT_TITLE: Commensal modulation of Peri-implant Microbiome Dysbiosis via Veillonella parvula


ED_INST_TYPE: GRADUATE SCHOOLS

FUNDING_MECHANISM: OTHER RESEARCH-RELATED

NIH_SPENDING_CATS: Cancer;Cancer Genomics;Digestive Diseases;Genetics;Hematology;Hepatitis;Hepatitis - B;Human Genome;Infectious Diseases;Liver Cancer;Liver Disease;Rare Diseases

ORG_CITY: NEW YORK

ORG_DEPT: ANATOMY/CELL BIOLOGY

ORG_NAME: ROCKEFELLER UNIVERSITY

ORG_STATE: NY

PHR: PROJECT NARRATIVE Chromatin, the protein-DNA complex responsible for genome organization, is tightly regulated to control gene expression, and aberrant chromatin regulation has been implicated in a wide variety of cancers and other diseases. The F99 portion of this proposal seeks to investigate mechanisms by which the oncovirus Hepatitis B Virus evades host regulatory pathways to maintain a stable minichromosome and promote oncogenesis within chronically infected cells. The K00 phase of this proposal shifts from focusing on HBV as a case-study of chromatin regulation to structurally and functionally interrogating healthy and oncogenic mutants of the CHD class of chromatin remodeling enzymes, which have diverse roles in modulating chromatin architecture.

PI_NAMEs: PRESCOTT, NICHOLAS  (contact)

PROGRAM_OFFICER_NAME: DAMICO, MARK W

PROJECT_TERMS: Address;Architecture;ATP Hydrolysis;Binding;Biochemical;Biochemistry;Biology;biophysical analysis;Biophysics;Cancer Biology;cancer type;career;Case Study;Cell Line;Cell Physiology;Cells;Cellular biology;Chemicals;Chromatin;Chromatin Fiber;chromatin remodeling;Chromatin Remodeling Factor;Chromatin Structure;Chronic;Chronic Hepatitis B;chronic infection;Circular DNA;clinically relevant;Complex;crosslink;Cryoelectron Microscopy;Data;Detection;Disease;DNA;Enzymes;Epigenetic Process;epigenome;epigenomics;established cell line;Eukaryotic Cell;experience;Faculty;Family;Functional disorder;Gatekeeping;Gene Expression;Gene Expression Profiling;gene-editing approach;Genetic Transcription;Genome;Genome Stability;Genomics;Goals;HELLS gene;Hepatitis B Virus;Hepatocyte;Histones;Homeostasis;Host Defense;Immune Evasion;improved;In Vitro;Individual;insight;Investigation;Knock-out;leukemia;Libraries;Maintenance;Malignant neoplasm of liver;Malignant Neoplasms;Mass Spectrum Analysis;member;Molecular and Cellular Biology;Molecular Biology;Molecular Conformation;mutant;Mutate;Mutation;novel strategies;novel therapeutics;Nucleosome Core Particle;Nucleosomes;Oncogenic;Oncornaviruses;Output;overexpression;Pathologic;Phase;Play;Population;Positioning Attribute;Post-Translational Protein Processing;Postdoctoral Fellow;Primary carcinoma of the liver cells;Proteins;Proteomics;Recombinants;reconstitution;recruit;Regulation;Regulatory Pathway;Research;Research Project Grants;Resolution;response;Rest;Role;Signal Transduction;skills;Stimulus;structural biology;Structure;System;Techniques;Technology;Testing;Therapeutic Intervention;transcription factor;transcriptome;tumorigenesis;Viral Proteins;Virus;Virus Replication;Work

PROJECT_TITLE: Regulation of Genome Stability and Structure by the Nucleosome Remodeler HELLS in Leukemia


ORG_CITY: Los Angeles

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_NAME: UNIVERSITY OF SOUTHERN CALIFORNIA

PHR: Overall Program Narrative This Program Project will develop novel statistical methods for integrating multiple data types to address the etiology and prognosis of cancer through a collaboration across four closely related projects, drawing upon the resources of three shared facility cores and coordinated by an administrative core. This goal will be achieved by a combination of methodological developments, simulation studies closely keyed to real data projects, user-friendly software packages that implement new methods, and applications to several studies of cancer.

PI_NAMEs: GAUDERMAN, WILLIAM JAMES (contact);SIEGMUND, KIMBERLY D

PROGRAM_OFFICER_NAME: ROTUNNO, MELISSA

PROJECT_TERMS: Address;anti-cancer research;Area;Automated Annotation;Big Data;Bioinformatics;bioinformatics resource;Biological;cancer epidemiology;Cancer Etiology;cancer genetics;Cancer Prognosis;cancer risk;cancer therapy;Clinical;Clinical Data;Clinical Research;Clinical Trials;Collaborations;Communities;Complex;Computer software;Constitution;Core Facility;Data;Data Analyses;data integration;data resource;Data Set;Databases;design;Development;Disease;DNA Methylation;Environmental Risk Factor;epidemiologic data;Epidemiologist;epidemiology study;Etiology;feature selection;Foundations;gene environment interaction;Gene Expression;gene function;Gene set enrichment analysis;Generations;Genes;genetic association;genetic epidemiology;Genetic Transcription;Genome;genome wide association study;genomic variation;Genomics;Genotype;Genotype-Tissue Expression Project;Goals;Heredity;high dimensionality;Infrastructure;Intervention;Knowledge;longitudinal analysis;Malignant Neoplasms;Measures;Mediation;member;metabolome;metabolomics;Methodology;Methods;methylome;microbiome;Modeling;modifiable risk;Multiomic Data;multiple data types;novel;novel strategies;Ontology;Pathway interactions;Phylogenetic Analysis;predictive modeling;preventive intervention;Prognosis;programs;Proteome;Research Personnel;Research Project Grants;Resources;Risk Factors;risk prediction;risk prediction model;Sample Size;Scanning;simulation;software development;Software Tools;Source;Spectrum Analysis;Statistical Data Interpretation;Statistical Methods;statistics;Structure;Therapeutic Intervention;Time;Tissues;tool;Training;trait;transcriptome;transcriptomics;Translational Research;Translations;user friendly software;Work

PROJECT_TITLE: Statistical Methods for Integrative Genomics in Cancer


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Cancer Genomics;Genetics;Human Genome;Networking and Information Technology R&D (NITRD)

PHR: Project 1: Narrative Associated with high-dimensional omic features there is a rich set of functional and regulatory  annotations, pathway information, and disease-specific knowledge from previous studies that is  routinely used to interpret analyses of omic data. In this project, we propose to develop integrative  high-dimensional regression methods capable of incorporating this array of external information  a priori, to improve prediction performance, selection of predictive and associated features, and  to gain insight into potential biological mechanisms.

PI_NAMEs: LEWINGER, JUAN PABLO  (contact)

PROJECT_TERMS: Address;Assessment tool;Biological;Chromosome Mapping;Colorectal Cancer;Complex;computerized tools;Data;Data Analytics;Data Correlations;data integration;Data Set;Diagnostic;diagnostic signature;diagnostic tool;Disease;Disease Outcome;DNA;DNA Integration;Elements;Enhancers;epigenomics;Evaluation;Event;feature selection;flexibility;Gene Expression;Gene Expression Profiling;Genes;Genetic Transcription;genome wide association study;Genomics;Goals;high dimensionality;improved;insight;Joints;Knowledge;Link;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Mediating;Methods;Modeling;Molecular;novel;Outcome;Pathway interactions;Performance;Play;Population;predictive modeling;prognostic;prognostic signature;prognostic tool;Regulatory Element;Risk Factors;Role;Scanning;Statistical Methods;Time;tool;trait;Transcriptional Regulation;transcriptomics;Untranslated RNA;Variant;Work

PROJECT_TITLE: High-Dimensional Regression for Data Integration


NIH_SPENDING_CATS: American Indian or Alaska Native;Cancer;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Racial and Ethnic Minority Health Research

PI_NAMEs: GILLETTE, JENNIFER  (contact)

PROJECT_TERMS: Advisory Committees;Age;American Indians;anti-cancer research;Applications Grants;Appointment;Arts;Award;Basic Cancer Research;Basic Science;behavior measurement;Cancer Biology;cancer care;Cancer Center Support Grant;cancer health disparity;cancer therapy;care delivery;career;Career Choice;career development;Career Exploration;Catchment Area;Centers of Research Excellence;Classification;Clinical;clinical care;clinical development;Clinical Sciences;clinical translation;Clinical Trials;college;community based participatory research;community engagement;community intervention;Community Outreach;Comprehensive Cancer Center;Data;Development;Discipline of Nursing;Disparity;Diverse Workforce;Doctor of Philosophy;economic disparity;Education;education research;Educational Curriculum;Educational workshop;Eligibility Determination;Engineering;Enrollment;Environment;Equity;ethnic diversity;Extramural Activities;Face;Faculty;Fellowship;Fellowship Program;Funding;Gender;gender diversity;Geography;Goals;Grant;hackathon;Health;health equity;Health Sciences;high school;Hispanic;hispanic community;improved;Indigenous American;Individual;Infrastructure;Institution;instrumentation;Interdisciplinary Study;interest;International;Leadership;Logic;Malignant Neoplasms;medical schools;medically underserved;meetings;member;Mentored Clinical Scientist Development Program;Mentors;Mentorship;Minority-Serving Institution;Mission;Modeling;multidisciplinary;NCI Center for Cancer Research;New Mexico;Not Hispanic or Latino;Outcome;Peer Review;Pharmacy facility;Population;population health;Population Sciences;Productivity;Program Development;Program Evaluation;programs;prospective;Public Health;Publications;racial diversity;recruit;Research;Research Personnel;Research Training;Resource Sharing;Resources;satisfaction;Schools;Science;Series;Services;Shapes;skill acquisition;skills;Students;success;Surveys;Training;Training and Education;Training Programs;Training Support;translational cancer research;Translational Research;Travel;underserved community;United States National Institutes of Health;Universities

PROJECT_TITLE: Cancer Research Training and Education Coordination Core


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Cancer Genomics;Data Science;Genetics;Human Genome

PHR: Project 1: Integration of Omic Data to Estimate Mediation or Latent Structures  Project Narrative This project focuses on the development of statistical approaches for the integration of multiple omics data that  are suspected, a priori, to act on a disease or trait outcome via mediation or a latent structured model. The  approaches span the analysis of studies with multiple omic measures on the same individuals to summary  statistics from omic data measured from multiple studies. These methods will have a direct impact on applied  investigations by facilitating a better understanding of potential biological mechanisms driving underlying  cancer etiology via identifying novel factors, estimating connections between those factors, and identifying  subgroups of individuals with potentially different associated mechanisms.

PI_NAMEs: CONTI, DAVID V (contact)

PROJECT_TERMS: Area;Automobile Driving;Biological;Biological Markers;Biology;Cancer Etiology;cancer genomics;Colorectal Cancer;Complex;Computer software;Data;data integration;data reduction;Data Set;Development;Disease;Disease Outcome;Etiology;Exposure to;FAIR principles;feature selection;Gene Expression;Genes;Genetic;genome wide association study;Genomics;Germ Lines;Goals;Heterogeneity;Individual;innovation;instrument;interest;Investigation;Joints;Malignant neoplasm of prostate;Malignant Neoplasms;Mathematics;Measurement;Measures;Mediating;Mediation;Mediator;metabolomics;Methodology;Methods;microbiome;Modeling;Molecular;multidimensional data;Multiomic Data;multiple data types;multiple omics;novel;Outcome;Pathway interactions;phenomics;Phenotype;pleiotropism;Population;Population Study;Process;programs;Proteomics;Research;Risk;Risk Factors;Specific qualifier value;Statistical Methods;statistics;Structure;Subgroup;Techniques;Technology;Testing;The Cancer Genome Atlas;Time;Tissues;trait;transcriptomics;Translations;user friendly software


ORG_CITY: LA JOLLA

ORG_DEPT: PHARMACOLOGY

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN DIEGO

PHR: Narrative The UC San Diego Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program seeks to employ a faculty cohort model to transform cultures of inclusive excellence and sustain our commitment to diversity and inclusion in biomedical research. We will create and foster an institutional environment of faculty hiring, sponsorship, continual mentoring, and support for professional development to cultivate an academic culture of inclusive excellence. We will develop and implement an evaluation plan to demonstrate how cluster hires and implementation of structured system-wide evidence-based faculty development programs enhance underrepresented faculty academic advancement and success, lead to institutional inclusive excellence, increase diversity and improve institutional climate for all faculty.

PI_NAMEs: MARTINEZ, MARIA ELENA;TREJO, JOANN  (contact)

PROGRAM_OFFICER_NAME: CALZOLA, JESSICA MARIE

PROJECT_TERMS: Address;Advanced Development;Area;Award;Biomedical Research;California;career;career development;career networking;cohort;Collaborations;Common Data Element;Communication;community building;Data;Databases;Development;Development Plans;diversity and inclusion;Elements;Environment;Equity;equity, diversity, and inclusion;Ethnic Origin;Ethnic Population;Evaluation;evidence base;Evidence based practice;expectation;Faculty;Faculty Recruitment;faculty support;Fostering;Funding;Goals;health equity;improved;Individual;innovation;Institution;Knowledge;Lead;Leadership;Mentors;Mentorship;Modeling;organizational climate;Participant;Population;Positioning Attribute;Productivity;Program Development;programs;Protocols documentation;Race;Recommendation;recruit;Research;research and development;Scientist;Secure;Strategic Planning;Structure;success;supportive environment;System;Teacher Professional Development;Theoretical model;United States National Institutes of Health;Universities;Woman;women faculty;women of color

PROJECT_TITLE: UC San Diego FIRST Program


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Cancer Genomics;Colorectal Cancer;Digestive Diseases;Genetics;Human Genome

PHR: Project 2: Narrative  The availability of high-volume ‘omic’ data, including gene expression, metabolome, methylation, and  microbiome, provides new opportunities to identify gene-environment (G×E) and omic × E interactions.  This project will develop statistical methods to leverage omic data to improve power for identifying  novel interactions as well as to inform the biological mechanism by which genes and exposures affect  cancer outcomes.

PI_NAMEs: GAUDERMAN, WILLIAM JAMES (contact)

PROJECT_TERMS: Accounting;Address;Affect;Alcohols;Biological;Biological Markers;Cancer Etiology;Cancer Prognosis;cancer therapy;cancer type;case control;clinical investigation;Clinical Research;Clinical Trials;Code;cohort;Collaborations;Colon;colon cancer patients;Colorectal Cancer;Complex;Data;Data Analyses;data resource;design;Dimensions;empowerment;Environment;Environmental Exposure;epidemiology study;gene discovery;gene environment interaction;Gene Expression;Genes;Genome Scan;Genomics;Genotype;Germ Lines;guided inquiry;high dimensionality;improved;Joints;Linkage Disequilibrium;Malignant Breast Neoplasm;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Measures;Meat;metabolome;metabolomics;method development;Methods;Methylation;microbiome;Modeling;Molecular;multi-ethnic;Normal tissue morphology;novel;Obesity;Organoids;Outcome;Pathway interactions;Patient-Focused Outcomes;Process;Questionnaires;Research Design;Research Personnel;Resources;Risk;Risk Factors;Sampling;screening;simulation;Software Tools;Source;Statistical Methods;Statistical Models;Step Tests;Structure;Techniques;Testing;Time;Tobacco;trait;transcriptome;transcriptomics;Translating;Treatment outcome;user friendly software;Work

PROJECT_TITLE: Integration of Omic Data in the Analysis of Gene x Environment Interaction


ED_INST_TYPE: ORGANIZED RESEARCH UNITS

ORG_CITY: Chicago

ORG_DEPT: NEUROSCIENCES

ORG_NAME: NORTHWESTERN UNIVERSITY

ORG_STATE: IL

PHR: PROJECT NARRATIVE The proposed research will develop a new, promising, and clinically relavant class of nanotherapeutics – spherical nucleic acids (SNAs) – as immunostimulatory agents for treating advanced melanoma, a disease where traditional cancer treatments including chemotherapy and radiation are largely ineffective, thereby significantly and positively impacting human health. SNAs offer an innovative approach to elucidate nanoscale structure-activity relationships, and deliver multiple immunostimulatory cues for generating enhanced antitumor responses. Broadly, this work will inform the rational design of new classes of cancer vaccines, resulting in significant advances in immunotherapy development for various forms of cancers.

PI_NAMEs: MIRKIN, CHAD A. (contact);ZHANG, BIN

PROGRAM_OFFICER_NAME: SINGH, ANJU

PROJECT_TERMS: Adjuvant;Agonist;Animals;anti-cancer research;anti-tumor immune response;Antigen Presentation;Antigen Targeting;Antigen-Presenting Cells;antigen-specific T cells;Antigens;Antitumor Response;Architecture;Biodistribution;Biological Models;cancer therapy;Cancer Vaccines;CD4 Positive T Lymphocytes;CD8-Positive T-Lymphocytes;CD8B1 gene;Cells;chemical synthesis;Chemicals;Chemotherapy and/or radiation;Chemotherapy-Oncologic Procedure;Clinic;Clinical;clinical translation;Clinical Treatment;clinically relevant;Cues;cytotoxic CD8 T cells;design;Development;Disease;efficacy evaluation;Enhancement Technology;Ensure;Epitopes;Evaluation;Foundations;Future;Goals;Health;Human;humanized mouse;Immune;immune activation;immune checkpoint blockade;Immune Evasion;Immune response;immune stimulatory agent;Immune system;Immunity;Immunocompetent;Immunologic Stimulation;Immunotherapeutic agent;Immunotherapy;improved;In Vitro;in vitro testing;in vivo;in vivo evaluation;in vivo Model;Individual;Innate Immune Response;innovation;Intravenous;Kinetics;Malignant Neoplasms;Melanoma;Melanoma Cell;Melanoma patient;Melanoma Vaccine;melanoma-associated antigen;Modeling;Modification;Monophenol Monooxygenase;mouse model;Mus;Mutation;nanoparticle;nanoscale;Nanostructures;Nanotechnology;nanotherapeutic;neoantigens;nucleic acid structure;Nucleic Acid Vaccines;Nucleic Acids;Nucleosome Core Particle;Oligonucleotides;Outcome;Pathway interactions;patient subsets;Patients;Peptides;Performance;Phase Ib/II Clinical Trial;Phase Ib/II Trial;Phenotype;Positioning Attribute;preclinical study;prevent;programmed cell death ligand 1;programmed cell death protein 1;Proteins;Radial;Radiation;rational design;receptor;Research;research clinical testing;response;Route;Signal Pathway;SILV gene;Specimen;Spherical Nucleic Acids;stoichiometry;Structure;Structure-Activity Relationship;subcutaneous;success;T cell response;Technology;Testing;Therapeutic;three dimensional structure;TLR9 gene;trafficking;Translations;tumor;Tumor Burden;Tumor Escape;tumor microenvironment;uptake;Vaccination;Vaccine Design;Vaccines;Variant;Work

PROJECT_TITLE: Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic Acids


NIH_SPENDING_CATS: American Indian or Alaska Native;Behavioral and Social Science;Cancer;Cervical Cancer;Clinical Research;Colorectal Cancer;Digestive Diseases;Genetics;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Infectious Diseases;Lung;Lung Cancer;Prevention;Primary Health Care;Racial and Ethnic Minority Health Research;Rural Health;Sexually Transmitted Infections;Social Determinants of Health;Women's Health Research

PI_NAMEs: MISHRA, SHIRAZ I. (contact)

PROJECT_TERMS: Address;Air;American Indian community;American Indians;Analgesics;Anthropology;Arizona;Arsenic;Arts;Behavior Therapy;Behavioral;Behavioral Sciences;Bioinformatics;Biological Markers;Biometry;Breast;cancer care;Cancer Center;Cancer Center Support Grant;Cancer Control;cancer health disparity;cancer risk;Caring;Catchment Area;cellular oncology;Cervical Cancer Screening;Cervix Uteri;Clinical;Clinical Trials;cohort;Collaborations;college;Colorado;Colorectal;Colorectal Cancer;colorectal cancer screening;Communities;community advisory board;Community Clinical Oncology Program;community engaged research;community engagement;community intervention;Community Medicine;Community Outreach;community research;Comprehensive Cancer Center;Contracts;cooking;Data;Dermatology;Development;Disease;Disparity;Dissemination and Implementation;DNA Damage;Doctor of Philosophy;early detection biomarkers;Early Diagnosis;Education;Endometrial;Engineering;Environmental Exposure;Environmental Health;Environmental Pollutants;Environmental Risk Factor;Epidemiology;ethnic diversity;evidence base;Family Practice;follow-up;Funding;Future;Gallbladder;Genetic;Genomics;Genotype;Geography;Goals;Grant;Guidelines;health disparity;health economics;Health Services;Healthcare;Hepatitis C virus;Hispanic;Human Papilloma Virus Vaccination;Human Papillomavirus;implementation research;improved;improved outcome;Incidence;Inequity;Infrastructure;Internal Medicine;Intervention;Intervention Studies;Journals;Ketorolac;Kidney;Knowledge;Length;Liver;Lung;male;Malignant neoplasm of cervix uteri;Malignant neoplasm of lung;Malignant neoplasm of ovary;Malignant Neoplasms;medical schools;Melanoma;member;Metals;methylation biomarker;Minority;Molecular;Molecular Epidemiology;molecular oncology;Morbidity - disease rate;mortality;multi-ethnic;Mutation;NCI-Designated Cancer Center;neoplasm registry;New Mexico;Not Hispanic or Latino;Oncologist;Outcome;Ovarian;Particulate;Pathology;Patients;Pediatrics;Peer Review;Personal Satisfaction;Pharmacy facility;physical inactivity;Planet Earth;policy recommendation;Population;population based;Population Genetics;population health;Population Heterogeneity;Population Sciences;Populations at Risk;Primary Care;programs;prospective;Prostate;Publications;Publishing;racial diversity;Registries;Research;Research Institute;Research Priority;Resource Sharing;Resources;respiratory;Risk Behaviors;Risk Factors;risk prediction;Risk Reduction;Rural;Rural Community;Rural Population;Science;screening;screening disparities;Screening for cancer;screening guidelines;Smoker;socioeconomics;survivorship;Testing;Therapeutic Research;therapeutic target;Tissues;Tobacco;Training;Translations;tribal Nation;tumor;tumor registry;Underserved Population;Universities;Utah;Virus;working group;Zinc supplementation

PROJECT_TITLE: Cancer Control and Population Science


PHR: Project Narrative Understanding the role that genes play in life is a key issue in biomedical sciences, yet the overwhelming majority of sequences in public databases remain uncharacterized. Functional annotation is important for a variety of downstream analyses of genetic data, yet experimental characterization of function remains costly and slow. This project therefore proposes three Aims focused on improving our understanding of functional genomics, thereby allowing better translation of data to knowledge impacting human health.

PI_NAMEs: MARJORAM, PAUL  (contact)

PROJECT_TERMS: Biological;bisulfite sequencing;Cancer cell line;Cells;Collaborations;Computer software;Computing Methodologies;cost;Data;Data Analyses;data to knowledge;Databases;Dependence;Development;DNA Methylation;drug sensitivity;Epigenetic Process;epigenome;experimental analysis;Family;functional genomics;gene function;gene interaction;Gene Silencing;Genes;Genetic;genetic analysis;Genome;genome-wide;Genomics;Health;Heterogeneity;Human;Hypermethylation;improved;interest;Joints;Knowledge;lens;Libraries;Life;Malignant Neoplasms;Maps;Measures;member;Methods;Methylation;model building;Modeling;Normal tissue morphology;novel;Ontology;Pathologist;Pathway Analysis;Pathway interactions;personalized medicine;Phenotype;Phylogenetic Analysis;Play;programs;public database;query tools;Recording of previous events;Research Personnel;Resources;Role;Science;Specificity;Statistical Data Interpretation;Statistical Methods;Structure;tool;Translating;Translations;Trees;tumor;Variant;whole genome;Work

PROJECT_TITLE: Statistical Methods for Genome Characterization


ORG_NAME: BAYLOR COLLEGE OF MEDICINE

PHR: OVERALL NARRATIVE Cellular immunotherapy has enormous potential to improve the therapy of lymphoma. The SPORE research plan outlined in this renewal application seeks to develop more effective cellular immunotherapies by increasing their antitumor activity against lymphomas in children and adults, reducing treatment-related complications, and simplying therapies to use banked allogeneic products that are immediately available. Results of these studies will lay the foundation for future comparative trials and licensing investigations.

PI_NAMEs: BRENNER, MALCOLM K.;HESLOP, HELEN E (contact)

PROGRAM_OFFICER_NAME: KUZMIN, IGOR A

PROJECT_TERMS: Address;Adult;Allogenic;alpha-beta T-Cell Receptor;anti-tumor immune response;Antibodies;Antigen Targeting;Antigens;Autologous;B-Cell Lymphomas;beta-2 Microglobulin;Biological;cancer cell;CD19 gene;cell bank;cell preparation;Cell Therapy;Cells;Cellular immunotherapy;checkpoint inhibition;Child;chimeric antigen receptor;chimeric antigen receptor T cells;Clinic;Clinical;Clinical Investigator;Clinical Research;clinical translation;college;Combined Modality Therapy;comparative trial;Cytotoxic T-Lymphocytes;Dasatinib;Dinoprostone;Down-Regulation;early phase clinical trial;EBV specific T-cells;Effector Cell;effector T cell;Elements;Engineering;Ensure;Epstein-Barr Virus-Related Lymphoma;first-in-human;fitness;Foundations;Frequencies;Future;Gene Modified;Genes;Genetic;genetically modified cells;Glycolipids;Goals;Graft Rejection;Hodgkin Disease;Hospitals;Human Herpesvirus 4;Immune;Immune Evasion;Immune response;Immune system;Immunotherapy;improved;In complete remission;in vivo;insight;Interleukin 7 Receptor;Interleukin-15;invariant chain;Investigation;knock-down;Laboratories;Laboratory Scientists;Laboratory Study;Length;Licensing;Licensure;Lymphoma;Lymphoma cell;manufacture;Mediating;Medicine;Methodist Church;MHC Class II Genes;MicroRNAs;Morbidity - disease rate;mortality;Multicenter Trials;Natural Killer Cells;neoplastic cell;Non-Hodgkin's Lymphoma;novel;novel strategies;Orphan Drugs;Outcome;Patients;Phase I/II Trial;pre-clinical;precision medicine;Process;Productivity;programs;Property;receptor;Records;recruit;Research;Research Personnel;Research Support;Residual Neoplasm;Resistance;Resources;response;Safety;Signal Transduction;small hairpin RNA;small molecule;Source;Specificity;standard of care;Stress;success;T cell therapy;T memory cell;T-Cell Activation;T-Cell Lymphoma;T-Lymphocyte;Technology;Technology Transfer;Testing;TNFRSF8 gene;Toxic effect;Transforming Growth Factor beta;Translational Research;Treatment Efficacy;Treatment-related toxicity;tumor;Tumor Antigens;tumor microenvironment;Tumor-associated macrophages;tumor-immune system interactions;Viral Antigens;Virus

PROJECT_TITLE: SPORE in Lymphoma


PHR: Narrative The Administrative Core will provide scientific oversight, enhance communications among investigators, and support all of the day-to-day administrative needs of this program. It will work proactively to assure complete synergy across the Research Projects and Cores around the theme of “statistical methods for integrative genomics” that is the focus of the Program.

PROJECT_TERMS: Advisory Committees;Bioinformatics;Biometry;Budgets;cancer genetics;Categories;Collaborations;Committee Members;Communication;Computer software;conflict resolution;design;Discipline;Education;Educational workshop;Elements;Ensure;Epidemiology;experience;Financial Activity;Genetic;genetic epidemiology;Genomics;Goals;High Performance Computing;Human Resources;Infrastructure;Leadership;Life;Malignant Neoplasms;meetings;Monitor;Nature;Occupational activity of managing finances;Postdoctoral Fellow;programs;Progress Reports;recruit;Reporting;Research;Research Personnel;Research Project Grants;Role;Schedule;Statistical Methods;Students;synergism;Travel;trend;web site;Work

PROJECT_TITLE: Core A: Administrative Core


ORG_NAME: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

PHR: OVERALL NARRATIVE The three projects of this P01 focus on allogeneic hematopoietic stem cell transplantation as a potentially curative therapy for many malignant diseases whose applicability has been impeded by the development of its most serious complication, GI GVHD. Projects 1 and 2 focus on the role of mitochondrial damage in intestinal stem cells and the role of the enzyme RIP1 that causes their death. Project 3 conducts two risk adapted clinical trials that determine treatment based on GI damage as measured by serum biomarkers.

PI_NAMEs: FERRARA, JAMES L. M. (contact)

PROGRAM_OFFICER_NAME: HENDERSON, LORI A

PROJECT_TERMS: Acceleration;Acute Graft Versus Host Disease;Allogenic;Animal Model;Bioenergetics;Biological Markers;Biology;Biopsy;Bone Marrow Transplantation;Cancer Patient;Cell Death;Cessation of life;Clinical Trials;Collaborations;Complication;curative treatments;Data;Defect;Development;Disease;Dose;Enzymes;gastrointestinal;Gastrointestinal tract structure;Goals;graft vs host disease;Hematopoietic Stem Cell Transplantation;Human;Inflammatory;inhibitor;innovation;insight;intestinal crypt;intestinal epithelium;Intestines;Laboratories;Malignant - descriptor;Measures;Mitochondria;Molecular;Morbidity - disease rate;mortality;Natural regeneration;novel;novel therapeutic intervention;Organ;Outcome;Pathway interactions;Patients;Phase II Clinical Trials;phase II trial;pre-clinical;prevent;Protein Kinase Interaction;real time monitoring;Receptor-Interacting Protein;Resistance;RIPK1 gene;Risk;Role;Sampling;Serum;stem cells;Steroids;Succinate Dehydrogenase;synergism;T-Cell Depletion;Testing;Therapeutic;Translating;translational model;translational progress

PROJECT_TITLE: Cellular and Molecular Studies of Bone Marrow Transplant


NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Genetics;Human Genome;Networking and Information Technology R&D (NITRD)

PHR: CORE B: NARATIVE The Functional Annotation Core (Core B) will continue to improve the Annotation Query (AnnoQ) system by improving the quality and performance of the system. The Core will work with the investigators in the Program to identify additional variants and annotation data to incorporate, and develop processes to perform quality control of the data. It will also develop appropriate IT strategies to ensure data integrity and security of the system, and develop additional software and packages to facilitate annotation data query. The Core has released the system to the public, and will provide training and support to the investigators within the Program and users in the research community.

PI_NAMEs: MI, HUAIYU  (contact)

PROJECT_TERMS: annotation  system;Benchmarking;Bioinformatics;bioinformatics infrastructure;Biology;Classification;Communities;Computer Security;Computer software;cyber security;Data;data integrity;data quality;Data Security;Data Set;Databases;dbSNP;design;Educational workshop;Enhancers;Ensure;Funding;gene function;Genes;Genetic;Genomics;Goals;Haplotypes;Happiness;improved;Infrastructure;Link;Malignant Neoplasms;meetings;member;method development;Modeling;novel;Ontology;outreach;Pathway interactions;Performance;Process;programs;Proteins;Quality Control;Research;Research Personnel;Resources;Scientist;Security;Series;Source;Statistical Methods;symposium;System;tool;trafficking;Training;Update;Variant;web site;webinar;Work

PROJECT_TITLE: Core B: Functional Annotation Core


NIH_SPENDING_CATS: American Indian or Alaska Native;Basic Behavioral and Social Science;Behavioral and Social Science;Biotechnology;Cancer;Cancer Genomics;Genetics;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Human Genome;Lung;Lung Cancer;Prevention;Racial and Ethnic Minority Health Research

PI_NAMEs: OZBUN, MICHELLE A (contact)

PROJECT_TERMS: Address;Affect;American Indians;Animal Model;anti-cancer research;Area;Arsenic;Automobile Driving;Autophagocytosis;Basic Science;Behavior;Behavioral;Biochemical;Biochemical Pathway;Biochemical Process;Bioinformatics;Biology;Biometry;cancer cell;Cancer Center Support Grant;Cancer Control;Cancer Etiology;cancer genome;cancer health disparity;cancer initiation;carcinogenesis;carcinogenicity;Catchment Area;Cell Communication;Cell Culture System;Cell model;Cell Physiology;Cells;cellular imaging;Centers of Research Excellence;Clinic;Clinical;Clinical Cancer Center;clinical translation;Collaborations;college;Communities;community setting;Comprehensive Cancer Center;Computer Models;Development;diagnostic biomarker;digital pathology;Direct Costs;Disparity;Doctor of Philosophy;environment related cancer;Environmental Carcinogens;Environmental Exposure;Environmental Pollutants;Epigenetic Process;Extramural Activities;Flow Cytometry;fundamental research;Funding;Genetic;Genetic study;Genome;genome sequencing;Genome Stability;genome-wide;Genomic approach;Genomics;Goals;Grant;Growth;high-throughput drug screening;hispanic community;Human;imaging platform;Imaging technology;Immunology;Incidence;Indigenous American;Inflammation;innovation;interdisciplinary approach;Intervention;Laboratories;Malignant Neoplasms;medical schools;member;Mentors;Metabolism;microscopic imaging;model organism;Modernization;Molecular;Molecular and Cellular Biology;molecular oncology;mortality;Mutation;NCI Center for Cancer Research;New Mexico;Normal Cell;novel;Nuclear;oncology program;Pathway interactions;patient engagement;Peer Review;Pharmacy facility;Phenotype;Population;Population Research;Population Sciences;predictive modeling;Process;Prognostic Marker;programs;Publications;Regulation;Research;Research Institute;Research Personnel;Resource Sharing;respiratory;Risk Factors;RNA;Sampling;Science;Signal Pathway;Signal Transduction;spatiotemporal;superresolution microscopy;synergism;Technology;Therapeutic;Therapeutic Research;Tissue imaging;Tissues;Tobacco use;Training;Training Programs;Transcriptional Regulation;Translating;Translational Research;Translations;tumor initiation;tumor microenvironment;tumor progression;Ultraviolet Rays;United States National Institutes of Health;Universities;Uranium;Virus;working group

PROJECT_TITLE: Cellular and Molecular Oncology


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Cancer Genomics;Data Science;Dissemination and Implementation Research;Genetics;Human Genome;Networking and Information Technology R&D (NITRD)

PHR: Core C: Project Narrative Core C has the overall goal of providing researchers of the program project with support and guidance for all their computational needs. A consequence of our work implementing statistical methods developed by the project will be the design and creation of novel computational resources that enable those analyses. We anticipate that we will create numerous new libraries and software packages that will not only support our own developments but also serve the entire scientific community.

PROJECT_TERMS: Address;Algorithm Design;Algorithms;Award;Cloud Computing;cluster computing;Code;code development;Communities;Complex;Computer software;Computing Methodologies;computing resources;Conscious;Data;Data Analyses;design;Development;Diffusion;Documentation;Education;experience;Genomics;Goals;Guidelines;High Performance Computing;implementation process;Libraries;Malignant Neoplasms;member;Memory;Methods;multithreading;novel;parallel computer;Play;Process;programs;Research;Research Personnel;Research Project Grants;Resource Allocation;Role;Services;simulation;Software Design;software development;Software Tools;Speed;Statistical Computing;Statistical Methods;success;Techniques;Technology;Testing;tool;Work

PROJECT_TITLE: Core C: Computation and Software Development Core


PHR: PROJECT NARRATIVE The Data Analysis and Research Translation Core will facilitate the application of novel methods developed in this Program to the analysis of complex datasets, accelerating discoveries of genetic and environmental causes of cancer.

PI_NAMEs: SIEGMUND, KIMBERLY D (contact)

PROJECT_TERMS: Acceleration;Benchmarking;Biological;Biological Factors;Biological Process;Budgets;Cancer Etiology;Cancer Prognosis;cancer risk;Clinical Research;Colorectal Cancer;Communities;complex data;Computer software;Computing Methodologies;computing resources;Data;Data Analyses;data resource;Data Set;data sharing;Databases;Development;Education;Educational Materials;Educational process of instructing;Ensure;epidemiology study;FAIR principles;falls;Genetic;Genomics;Goals;Grant;Happiness;high dimensionality;Human Resources;insight;Malignant neoplasm of prostate;Malignant Neoplasms;member;Methods;Multiomic Data;novel;Outcome;Policies;Process;Prognosis;Program Accessibility;programs;Publishing;Reproducibility;Research;Research Personnel;Research Project Grants;research study;Resources;Running;Scientist;Series;Software Tools;Statistical Methods;Study Subject;Technology;tool;Training;training project;Translational Research;United States National Institutes of Health;Work

PROJECT_TITLE: Core D: Data Analysis and Research Translation Core


ADMINISTERING_IC: HL

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Cardiovascular;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Heart Disease;Nutrition;Obesity;Prevention;Racial and Ethnic Minority Health Research;Rural Health;Sleep Research;Social Determinants of Health

ORG_CITY: CORAL GABLES

ORG_DEPT: PSYCHIATRY

ORG_NAME: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE

ORG_STATE: FL

PHR: Project Narrative This proposal is predicated upon compelling data that Latino/as exhibit a greater risk of insufficient sleep (<7 hours) compared with whites, and that insufficient sleep is associated with increased risk of cardiovascular disease and inflammation. It will provide multi-level evidence on behavioral, genetic, psychosocial and environmental determinants of insufficient sleep and sleep-related CVD risk and inflammation markers among rural and urban Latino/as. These data will provide the foundation for interventions to mitigate adverse effects of insufficient sleep on health outcomes.

PI_NAMEs: SEIXAS, AZIZI  (contact)

PROGRAM_OFFICER_NAME: BAIZER, LAWRENCE

PROJECT_TERMS: actigraphy;Address;Adverse effects;Affect;Age;Air;arterial stiffness;Bayesian learning;Behavioral;Biological;Biometry;Birth Place;Blood Pressure;built environment;burden of illness;Cardiovascular Diseases;cardiovascular disorder risk;Cause of Death;Cessation of life;circadian;Circadian desynchrony;clinically actionable;Collection;Communities;community engaged research;Data;density;design;Devices;Diabetes Mellitus;Diet;Diet and Nutrition;Discrimination;disease disparity;Disease Marker;Disease Outcome;Disparity;diverse data;Dyslipidemias;Emotional;Enrollment;Environment;Environmental Risk Factor;Epidemiology;ethnic minority;ethnic minority population;Ethnic Population;Exhibits;experience;fasting plasma glucose;Foundations;Funding;Genetic;Genetic Markers;Genotype;Geographic Information Systems;Glucose;Glycosylated hemoglobin A;good diet;Health;health data;health disparity;High Prevalence;Home;Hour;Household;Hypertension;improved;Individual;Inflammation;Inflammatory;inflammatory marker;innovation;instrumentation;Insulin Resistance;Interleukin-10;Interleukin-6;Intervention;Latino;Length of Stay;Life;Life Style;Light;Link;Lipids;Machine Learning;Methodology;mHealth;Modeling;models and simulation;modifiable risk;Morbidity - disease rate;mortality;multidisciplinary;Nature;Neighborhoods;New York;Noise;Not Hispanic or Latino;novel;Obesity;Outcome;Overweight;Physical activity;Policies;population based;Population Study;Predictive Factor;Process;psychosocial;Psychosocial Factor;Public Health;racial minority;racial population;recruit;Reduce health disparities;Research;Research Personnel;response;Risk;Risk Factors;Risk Marker;Rural;rural area;Rural Community;rural setting;Sampling;Science;Seminal;sex;Sleep;Sleep Apnea Syndromes;Sleep Deprivation;Sleep Disorders;Sleeplessness;smoking cessation;social;Socioeconomic Status;Stress;success;System;Temperature;Time;TNF gene;tool;United States National Institutes of Health;urban area;Urban Community;urban disparity;urban setting

PROJECT_TITLE: DORMIR: Determinants, Outcomes, Responses and Markers of Insufficient sleep in Rural-Urban settings


PI_NAMEs: TREJO, JOANN  (contact)

PROJECT_TERMS: Administrator;Adopted;Advanced Development;Advisory Committees;Affinity;Area;Biochemistry;Biological Sciences;Biomedical Research;California;Cardiovascular Diseases;career development;Chemistry;climate data;Cognitive Science;cohort;Collaborations;Collection;Communicable Diseases;Communication;Competence;Coupled;Data;Development;Disabled Persons;diversity and inclusion;Engineering;Ensure;Environment;equity, diversity, and inclusion;Ethnic Population;Evaluation;Evaluation Methodology;evidence base;Evidence based program;expectation;experience;Faculty;flexibility;Fostering;Funding;Goals;Grant;Health Sciences;Human;Immersion;Immunology;Individual;Infrastructure;Institution;Leadership;Longevity;Malignant Neoplasms;medical schools;Mentors;Mentorship;Methodology;Modeling;Neurosciences;Oceanography;operation;Organizational Change;Organizational Culture;outreach;Participant;Perception;Pharmacy facility;physical science;Process;Productivity;Program Development;Program Sustainability;programs;Protocols documentation;Public Health Schools;racial population;recruit;Research;research and development;Resources;retention rate;satisfaction;Schools;Science;Social Sciences;Strategic Planning;Structure;success;System;Teacher Professional Development;tool development;United States National Institutes of Health;Universities;Vision;Woman;Work

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-MOSS-X]


NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Brain Cancer;Brain Disorders;Cancer;Clinical Research;Networking and Information Technology R&D (NITRD);Neurosciences;Rare Diseases

ORG_CITY: MINNEAPOLIS

ORG_DEPT: RADIATION-DIAGNOSTIC/ONCOLOGY

ORG_NAME: UNIVERSITY OF MINNESOTA

PHR: PROJECT NARRATIVE Magnetic resonance spectroscopy (MRS) can provide metabolic information noninvasively for assessment of tumor type and treatment response in any body part. The clinical impact of MRS has been limited by the technical expertise required to make these measurements. This research project will develop and evaluate automated tools to make MRS measurements easier and more robust for both research and clinical uses.

PI_NAMEs: MARJANSKA, MALGORZATA  (contact)

PROGRAM_OFFICER_NAME: KIM, BOKLYE

PROJECT_TERMS: 19q;3-Dimensional;Adoption;Adult;Anatomy;anti-cancer research;arm;automated analysis;Automation;Back;Biological Markers;Body part;Body System;Brain Neoplasms;Calibration;cancer therapy;Choline;Chromosomal Loss;Clinical;clinical practice;Clinical Research;clinical research site;Communities;Computer software;Cystathionine;Data;data acquisition;Data Analyses;Data Set;deep neural network;Exhibits;Glioma;heuristics;image guided;improved;informatics tool;interest;Isocitrate Dehydrogenase;Judgment;Lesion;Magnetic Resonance Imaging;Magnetic Resonance Spectroscopy;Malignant neoplasm of brain;Malignant Neoplasms;Measurement;Measures;Metabolic;Methods;Molecular;Monitor;Morphologic artifacts;Multi-Institutional Clinical Trial;Mutation;Normal tissue morphology;novel;open source;open source tool;Pathologic;Patient Care;Patients;Performance;Phenotype;Phospholipid Metabolism;Physiologic pulse;Positioning Attribute;prevent;Procedures;Research;Research Personnel;Research Project Grants;Scanning;Site;skills;Source;Spectrum Analysis;System;Technical Expertise;Techniques;Time;tool;Training;translational barrier;transmission process;treatment response;tumor;tumor progression;Vendor;Water

PROJECT_TITLE: Developing informatics tools for optimized MRS for brain cancer research


PI_NAMEs: REZNIK, VIVIAN  (contact)

PROJECT_TERMS: Acceleration;Advanced Development;Area;Award;Budgets;California;career;career development;career networking;cohort;Collaborations;Communities;community building;Competence;design;Development;Development Plans;Educational process of instructing;Elements;Environment;Equity;Ethnic Origin;Ethnic Population;evidence base;Faculty;faculty support;Fostering;Funding;Goals;Grant;health equity;improved;innovation;Institution;Intervention;Knowledge;Leadership;Manuscripts;Mentors;Mentorship;Methodology;Organizational Culture;Participant;patient engagement;peer;peer coaching;Population;Positioning Attribute;Preparation;Process;Productivity;Program Development;programs;Race;Recommendation;recruit;Research;research and development;research faculty;Research Personnel;Research Training;Schools;Scientist;senior faculty;Services;skills;Structure;success;System;Teacher Professional Development;Training Programs;United States National Institutes of Health;Universities;Woman;women faculty;women of color;Writing


NIH_SPENDING_CATS: American Indian or Alaska Native;Bioengineering;Biotechnology;Cancer;Cancer Genomics;Genetics;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Human Genome;Immunization;Immunotherapy;Precision Medicine;Prevention;Racial and Ethnic Minority Health Research;Vaccine Related

PI_NAMEs: PROSSNITZ, ERIC R (contact)

PROJECT_TERMS: Advanced Malignant Neoplasm;Advisory Committees;Aerosols;Agonist;American Indian community;Animal Model;anti-CTLA4 antibodies;Antibodies;Antineoplastic Agents;Area;Cancer Biology;Cancer Center Support Grant;cancer clinical trial;Cancer Control;cancer genome;cancer imaging;cancer prevention;cancer therapy;Cancer Vaccines;Catchment Area;Certification;Chemistry;CLIA certified;Clinical;Clinical Protocols;Clinical Research;Clinical Trials;Clinical Trials Network;Collaborations;college;Combined Modality Therapy;community intervention;Complex;Correlative Study;CTLA4 gene;Data;Data Analyses;data warehouse;design;Development;Discipline;Disease;Doctor of Philosophy;Drug Delivery Systems;drug discovery;Drug Formulations;Drug Targeting;Engineering;Evaluation;Faculty;FDA approved;first-in-human;Foundations;functional genomics;Funding;Future;G-Protein-Coupled Receptors;Genetic Counseling;Genome;genome sequencing;genomic data;Genomics;Goals;GPER gene;Grant;high throughput screening;Image;imaging agent;immune checkpoint;improved;Indigenous American;Informatics;Infrastructure;innovation;innovative technologies;Integrins;Intellectual Property;Intervention Community Trial;Intervention Trial;investigator-initiated trial;Leadership;Legal patent;Ligands;Link;Malignant neoplasm of ovary;Malignant Neoplasms;medical schools;meetings;member;Methods;Minority;Modeling;Molecular;molecular oncology;molecular targeted therapies;multi-ethnic;Multicenter Trials;nanoparticle;National Clinical Trials Network;neoplastic cell;New Agents;New Mexico;novel;novel anticancer drug;novel diagnostics;novel drug combination;novel therapeutic intervention;Outcome;patient engagement;Patient Selection;Patients;Peer Review;Pharmaceutical Preparations;Pharmacy facility;Phase;phase I trial;Phase I/II Clinical Trial;phase II trial;Play;Poly(ADP-ribose) Polymerase Inhibitor;Population;Population Sciences;pre-clinical;Pre-Clinical Model;precision medicine;preclinical study;predictive marker;Process;programs;Publishing;Randomized;receptor;recruit;Recurrence;Regimen;Research;Research Institute;Research Personnel;resilience;Resource Sharing;respiratory;response biomarker;Schools;Science;Senior Scientist;Site;small molecule;System;Talents;targeted agent;targeted delivery;targeted treatment;Technology;technology development;technology platform;Therapeutic;Therapeutic Agents;Therapeutic Index;Therapeutic Intervention;Therapeutic Research;Therapeutic Trials;therapeutic vaccine;Translating;translational pipeline;Translational Research;translational research program;translational therapeutics;Translations;Treatment Efficacy;treatment optimization;Underserved Population;United States National Institutes of Health;Universities;Vaccine Design;vaccine platform;Virus-like particle;working group

PROJECT_TITLE: Cancer Therapeutics


NIH_SPENDING_CATS: Clinical Research

PI_NAMEs: WINGARD, DEBORAH L (contact)

PROJECT_TERMS: Address;Advanced Development;base;Behavior;Biochemistry;Biological Sciences;California;career;career development;Chemistry;Climate;Cognitive;Cognitive Science;cohort;Collaborations;Common Data Element;Competence;Data;Data Collection;Data Sources;Databases;demographics;Development;diversity and inclusion;Effectiveness;Elements;Engineering;Environment;Ethnic Origin;Evaluation;evidence base;Evidence based practice;Faculty;Focus Groups;Fostering;Funding;Goals;Grant;health equity;Health Sciences;Health Surveys;Human;Immersion;improved;Individual;innovation;Institution;Interview;Knowledge;Leadership;Longevity;medical schools;Mentors;Mentorship;model design;Modeling;Monitor;Morale;Oceanography;organizational climate;Organizational Culture;Outcome;Participant;Perception;Pharmacy facility;physical science;Population;Productivity;Program Development;programs;Public Health Schools;Publications;Race;recruit;Research;research and development;satisfaction;Schools;Secure;Self Efficacy;Self-Examination;skills;social;Social Sciences;Structure;success;Surveys;System;Teacher Professional Development;Testing;Theoretical model;theories;United States National Institutes of Health;Universities;Woman


NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cardiovascular;Heart Disease;Pediatric;Pediatric Cardiomyopathy;Rare Diseases

ORG_CITY: SEATTLE

ORG_NAME: UNIVERSITY OF WASHINGTON

ORG_STATE: WA

PHR: Project Narrative  The objective of this project is to develop a catheter ablation system that uses high-intensity ultrasound energy to selectively ablate the mid-interventricular septum of the heart, as a potential treatment for obstructive hypertrophic cardiomyopathy (HCM). This device and approach has several advantages over existing septal reduction therapies for HCM in that it is less invasive, independent of variabilities in patient anatomy, and may spare the His-Purkinje system resulting in a lower incidence of atrio-ventricular block and pacemaker implantation. Incorporation of cardiac imaging features into the catheter to both track its location as well as to confirm creation of durable lesions will improve both safety and efficacy of the procedure.

PI_NAMEs: NAZER, BABAK  (contact)

PROGRAM_OFFICER_NAME: HALLER, JOHN WAYNE

PROJECT_TERMS: 3-Dimensional;Ablation;Acoustics;Alcohols;Anatomy;animal data;Animal Experimentation;Animals;Arrhythmia;Arteries;Atrioventricular Block;Award;Bundle-Branch Block;Cardiac ablation;cardiac magnetic resonance imaging;Catheters;Chest Pain;Cicatrix;Clinical;Complication;Coronary artery;coronary fibrosis;Custom;design;Development;Devices;Disease;Documentation;Dyspnea;Echocardiography;Electrophysiology (science);Endocardium;Ensure;ex vivo perfusion;fabrication;Family suidae;Feasibility Studies;Femur;Fibrosis;first-in-human;follow-up;Frequencies;Genetic Diseases;Gold;Health Services Accessibility;Heart failure;heart imaging;Heart Septum;high risk;Histology;Hypertrophic Cardiomyopathy;Hypertrophy;Image;image processing;implantation;improved;in vivo;Incidence;indexing;Laboratories;Left;Lesion;Location;Maps;Mechanics;Methods;Modeling;Morbidity - disease rate;mortality;mortality risk;multidisciplinary;Myocardial;Myocardial perfusion;novel;novel strategies;Obstruction;Operative Surgical Procedures;Pacemakers;Pathology;Patients;Perioperative;Physics;Physiologic pulse;porcine model;Positioning Attribute;preclinical efficacy;preclinical safety;Procedures;Process;prototype;Radial;real time monitoring;reduce symptoms;Research;Research Methodology;Research Personnel;Resolution;Right ventricular structure;Risk;Risk Reduction;Safety;Signal Transduction;simulation;simulation software;Sonication;Statistical Study;Sudden Death;Symptoms;System;Testing;Therapeutic;Thick;Time;Tissues;Transducers;Translating;Translations;Ultrasonic Therapy;Ultrasonic Transducer;ultrasound;ultrasound ablation;Validation;Venous;Ventricular;Ventricular septum;Work

PROJECT_TITLE: High-Intensity Ultrasound Ablation for Septal Reduction Therapy of Hypertrophic Cardiomyopathy

STUDY_SECTION: BTSS

STUDY_SECTION_NAME: Bioengineering, Technology and Surgical Sciences Study Section[BTSS]


NIH_SPENDING_CATS: Cancer;Genetics;Hematology;Orphan Drug;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human

PHR: NARRATIVE The proposed research is relevant to public health because it will expand fundamental knowledge of the molecular factors that govern malignant stem cell generation in multiple myeloma, the second most common blood cancer in the United States. The interferon-response factor 4 (IRF4) pathway contributes to malignant tumor cell growth and survival in this fatal disease, however the extent to which IRF4 controls cancer stem cell activity remains unknown. This project is relevant to NIH’s mission because it will test a novel RNA-based inhibitor in pre-clinical combination drug treatment studies that have high potential to help reduce illness and disability for patients with multiple myeloma.

PI_NAMEs: CREWS, LESLIE A (contact)

PROGRAM_OFFICER_NAME: HOWCROFT, THOMAS K

PROJECT_TERMS: adenosine deaminase;Antibody-Producing Cells;Antisense Oligonucleotide Therapy;Antisense Oligonucleotides;B-Lymphocytes;Biological Markers;Bone Marrow;Bortezomib;burden of illness;cancer cell;Cancer Control;cancer stem cell;cell growth;Cell Survival;Cell Transplantation;Cells;Cellular Assay;Clinical;clinical translation;clinically relevant;Combined Modality Therapy;cytokine;Data;Detection;Development;disability;Disease;Double-Stranded RNA;Drug Combinations;Drug resistance;Drug usage;experience;Gene Expression;Generations;Genes;Genetic;Genetic Transcription;Growth Factor;Hematopoietic Neoplasms;Hematopoietic stem cells;high risk;Human;Immune response;Impairment;In Vitro;in vivo;in vivo Model;Inflammation;Inflammatory;inhibitor;inhibitor therapy;innovation;Interferon Activation;Interferons;Investigation;knock-down;Knowledge;Lead;lenalidomide;Link;Lymphoid Cell;Malignant - descriptor;Malignant Neoplasms;Mission;Modeling;Molecular;Molecular Target;Multiple Myeloma;Natural regeneration;novel;novel therapeutics;Outcome;paracrine;Pathway interactions;Patients;PF4 Gene;Pharmaceutical Preparations;Pharmacotherapy;Phenotype;plasma cell development;Plasma Cell Neoplasm;Plasma Cells;Play;Positioning Attribute;pre-clinical;Pre-Clinical Model;prevent;Printing;progenitor;programs;Proteins;Public Health;Recurrent disease;Refractory;Relapse;Research;response;RNA;RNA-targeting therapy;Role;Sampling;self-renewal;Signal Transduction;small hairpin RNA;small molecule;standard of care;stem cell biology;stem cell genes;stem cell population;stem cells;stem-like cell;stemness;Stromal Cells;Survival Rate;synergism;System;targeted treatment;Testing;Therapeutic;Therapeutic Effect;therapeutic evaluation;therapeutic target;transcription factor;Translations;tumor;United States;United States National Institutes of Health;Work

PROJECT_TITLE: Core transcriptional regulators of malignant stem cell generation in multiple myeloma

STUDY_SECTION_NAME: Mechanisms of Cancer Therapeutics - 2 Study Section[MCT2]


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Hematology;Lymphatic Research;Lymphoma;Rare Diseases

PHR: NARRATIVE The Administrative Core supports the leadership of the overall Lymphoma SPORE to facilitate cooperation and communication between all Projects and Cores for the successful completion of the proposed research. This Core organizes meetings to monitor progress and promote collaboration and obtains external advice on program performance from Internal and External Scientific Advisory Boards. The Administrative Core also co-ordinates input from patient advocates and the Baylor College of Medicine Office of Diversity.

PI_NAMEs: HESLOP, HELEN E (contact)

PROJECT_TITLE: Administrative Core


NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cancer;Chronic Obstructive Pulmonary Disease;Data Science;Genetics;Lung;Lung Cancer;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Prevention

ORG_CITY: BOSTON

ORG_NAME: BRIGHAM AND WOMEN'S HOSPITAL

ORG_STATE: MA

PHR: PROJECT NARRATIVE Standard diagnostic practice for non-small cell lung cancer (NSCLC) focuses on nodular characteristics such as diameter and growth rate over sequential scans, thus ignoring important diagnostic features in the surrounding parenchyma such as emphysema and chronic inflammation that are associated with an increased risk of a nodule being malignant. Understanding the key parenchymal and tumor-specific features together with other biologic traits that determine whether a nodule is malignant or benign will improve early diagnosis of NSCLC. We will develop convolutional neural networks (CNNs) that utilize these features and traits to provide improved diagnostic accuracy of indeterminate pulmonary nodules seen in low-dose computed tomography images.

PI_NAMEs: MASQUELIN, AXEL HERVE PATRICK (contact)

PROJECT_TERMS: accurate diagnosis;Achievement;Address;adjudication;Age Years;airway obstruction;Anxiety;Attention;Benign;Biological;Biological Markers;Cancer Detection;cancer diagnosis;career;Characteristics;Chronic;Chronic Obstructive Pulmonary Disease;Classification;Clinical;clinically significant;computed tomography screening;convolutional neural network;cost;Data;Data Set;deep learning;deep neural network;Detection;Diagnostic;diagnostic accuracy;diagnostic biomarker;Diameter;directed attention;Early Diagnosis;Educational process of instructing;endophenotype;Failure;Fibrosis;follow-up;Foundations;Functional disorder;Future;Genetic;genetic variant;Genomics;Goals;Growth;Guidelines;Healthcare Systems;high risk;high risk population;Histologic;histological image;idiopathic pulmonary fibrosis;Image;imaging biomarker;improved;Individual;Inflammation;insight;Investigation;Knowledge;Learning;Left;low dose computed tomography;Lung;lung imaging;Lung nodule;Machine Learning;Malignant - descriptor;Malignant neoplasm of lung;Malignant Neoplasms;Measures;Medical;Methodology;Modality;model generalizability;Morphology;mortality;Network-based;neural network;Nodule;Non-Small-Cell Lung Carcinoma;novel;novel strategies;Outcome;Pathogenesis;Patients;Pattern;Performance;Phenotype;Physiological;Play;Precancerous Conditions;Predisposition;Procedures;Process;Pulmonary Emphysema;Pulmonary Inflammation;Quality of life;radiologist;Recommendation;Research Personnel;Risk;Risk Factors;Role;Scanning;screening;Sensitivity and Specificity;Single Nucleotide Polymorphism;Smoker;Smoking History;Solid;Specific qualifier value;Specificity;Spirometry;Testing;Training;training data;Training Programs;trait;tumor;United States Preventative Services Task Force;vector;Work

PROJECT_TITLE: Improving the Generalizability of Deep Neural Networks by Teaching Single Nucleotide Polymorphisms Associated with LDCT Features


NIH_SPENDING_CATS: Biotechnology;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Gene Therapy;Gene Therapy Clinical Trials;Genetics;Hematology;Immunotherapy;Lymphatic Research;Lymphoma;Orphan Drug;Rare Diseases

PHR: NARRATIVE Despite remarkable progress achieved with chimeric antigen receptor (CAR)-expressing T cells in the treatment of relapsed/refractory B lineage neoplasms, CD19-specific CAR (CAR.CD19) autologous T cell products are not curative for more than half of B-NHL patients. Thus, alternative sources of immune cells that may offer unique advantages over traditional T cells are urgently needed. This project will continue explore the clinical utility in lymphoma patients of “natural killer” T (NKT) cells expressing CAR molecules directed to the CD19 target antigen on tumor cells. NKT cells are promising candidates for immunotherapy because they do not induce graft-vs.- host disease and have multiple routes by which they can kill lymphoma cells.

PI_NAMEs: METELITSA, LEONID S (contact)

PROJECT_TERMS: Address;Adult;Affect;Allogenic;Antigen Targeting;Autologous;B-Cell Lymphomas;B-Cell NonHodgkins Lymphoma;beta-2 Microglobulin;Cancer Model;cancer type;candidate selection;CAR T cell therapy;CD19 gene;CD2 gene;CD8B1 gene;Cell Therapy;Cells;chimeric antigen receptor;Clinical;clinical investigation;cost;cost effective;Cytotoxic T-Lymphocytes;cytotoxicity;Development;Disease;Down-Regulation;Engineering;exhaustion;FDA approved;first-in-human;fitness;Foundations;Gene Expression Regulation;Genetic Transcription;Goals;Good Manufacturing Process;Graft Rejection;graft vs host disease;graft vs leukemia effect;Guidelines;high risk;Histocompatibility Antigens Class II;Image;Immune;Immune response;Immunologics;Immunotherapy;In complete remission;In Vitro;in vivo;Interleukin-15;knock-down;lymphoblast;Lymphoma;Lymphoma cell;Macrophage;Malignant Neoplasms;Measures;Mediating;MicroRNAs;Modeling;Molecular Analysis;Monitor;Myeloid-derived suppressor cells;National Cancer Institute;Natural Killer Cells;neoplasm immunotherapy;Neoplasms;neoplastic cell;non-Hodgkin's lymphoma patients;novel;overexpression;patient variability;Patients;pediatric patients;peripheral blood;pharmacologic;Phase I Clinical Trials;pre-clinical;Progressive Disease;promoter;Property;Publishing;Recurrence;Refractory;Relapse;research clinical testing;Resistance;response;RNA;Route;Safety;Self Direction;Series;Site;small hairpin RNA;Source;T cell therapy;T-Lymphocyte;Testing;Therapeutic;therapeutic evaluation;Toxic effect;Trans-Activators;Transgenic Organisms;tumor;Tumor Immunity

PROJECT_TITLE: Project 1: Immunotherapy of B cell lymphoma with NKT cells


NIH_SPENDING_CATS: Cancer;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research

PI_NAMEs: SANCHEZ, YOLANDA  (contact)

PROJECT_TERMS: Achievement;Address;Advisory Committees;American Indians;anti-cancer research;Area;authority;Automobile Driving;Basic Science;Cancer Burden;Cancer Center;Cancer Center Support Grant;cancer health disparity;cancer prevention;cancer research center director;cancer therapy;Catchment Area;Clinical;clinical care;Clinical Research;Collaborations;collaborative environment;community advisory board;community engagement;Community Outreach;Comprehensive Cancer Center;Decision Making;demographics;Diagnosis;Doctor of Philosophy;Education;Ensure;Environment;Ethnic Population;Evaluation;experience;Extramural Activities;Faculty;Fostering;Funding;Future;Goals;Grant;Growth;Health;Hispanic Populations;improved;Infrastructure;innovation;Interdisciplinary Study;Laboratories;Leadership;Malignant Neoplasms;meetings;member;Mentors;Mexican;Minority;Mission;Monitor;multi-ethnic;NCI Center for Cancer Research;New Mexico;Nursing Faculty;operation;Periodicals;Population;population based;Population Sciences;Poverty;prevent;Process;Productivity;programs;Recommendation;recruit;Research;Research Infrastructure;Research Institute;Resource Sharing;Resources;respiratory;Role;Strategic Planning;supportive environment;Training;Training and Education;Translational Research;Translations;Universities;Update;working group

PROJECT_TITLE: Leadership, Planning and Evaluation


NIH_SPENDING_CATS: Biotechnology;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Gene Therapy;Gene Therapy Clinical Trials;Genetics;Hematology;Immunotherapy;Lymphatic Research;Lymphoma;Orphan Drug;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation

PHR: NARRATIVE Patients who have T-cell lymphoma that does not respond to, or comes back after, treatment, do not have good oprions for treatment. We have shown that the patients’ own non-cancerous T cells can be modified with a gene that allows them to recognize and kill their malignant counterparts. We will now make these anti-cancer T cells more efficient, and then modify them further so that they can be made from healthy people in advance, and stored ready to use immediately for anyone with a T cell lymphoma.

PI_NAMEs: BRENNER, MALCOLM K. (contact)

PROJECT_TERMS: Acceleration;Address;Adoptive Cell Transfers;Allogenic;anti-cancer;Antigens;arm;Autologous;Automobile Driving;B lymphoid malignancy;B-Lymphocytes;Back;Behavior;CAR T cell therapy;Cell Lineage;cell preparation;Cell Therapy;Cells;chimeric antigen receptor;chimeric antigen receptor T cells;Clinic;Clinical;Clinical Data;Clinical Research;clinically significant;Cyclic GMP;Dasatinib;Disease;Disease Progression;donor stem cell;Engineering;Ensure;first-in-human;fitness;Frequencies;Funding;Genes;Goals;graft vs host disease;Hematopoietic Stem Cell Transplantation;Homing;Immune;improved;improved outcome;inhibitor;Learning;lymph nodes;Lymphoma;Malignant - descriptor;manufacture;Modification;novel;Outcome;patient subsets;Patients;Peripheral;Persons;pharmacologic;Phase;Phase I Clinical Trials;Population;pre-clinical;preservation;Property;Protocols documentation;receptor;receptor expression;Receptor Signaling;Recurrent disease;Refractory;Relapse;Resistance;response;Safety;success;T cell differentiation;T cell therapy;T memory cell;T-Cell Lymphoma;T-Cell Receptor Genes;T-Lymphocyte;T-Lymphocyte Subsets;Testing;Therapeutic;therapy resistant;tumor;Tyrosine Kinase Inhibitor;Undifferentiated

PROJECT_TITLE: Project 2: CAR-T cell therapy for T cell lymphoma


ED_INST_TYPE: SCHOOLS OF VETERINARY MEDICINE

NIH_SPENDING_CATS: Cancer;Cancer Genomics;Genetics;Human Genome;Immunotherapy;Orphan Drug;Rare Diseases;Urologic Diseases

ORG_CITY: WEST LAFAYETTE

ORG_DEPT: VETERINARY SCIENCES

ORG_NAME: PURDUE UNIVERSITY

ORG_STATE: IN

PHR: Project Narrative The proposed research is relevant to public health because greatly expanding the applicability of the canine invasive bladder cancer model, especially related to improving immunotherapy, will propel success in more fully understanding and effectively treating cancer in humans. This will impact NIH's mission toward human health by subsequently increasing the number of successes and limiting the number of failures in human clinical trials, thus ultimately preventing suffering, saving lives, and reducing health care costs of bladder cancer. The proof-of-concept work will also justify the identification of other naturally-occurring dog cancer models to improve therapy for other cancers.

PI_NAMEs: KNAPP, DEBORAH W (contact)

PROGRAM_OFFICER_NAME: HU, ZHANG-ZHI

PROJECT_TERMS: Address;Advanced Malignant Neoplasm;Adverse event;Affect;Animal Cancer Model;Animal Model;anti-PD-L1 antibodies;Behavior;Bioinformatics;cancer heterogeneity;cancer immunotherapy;Cancer Model;canine model;Canis familiaris;Cells;Cellular Indexing of Transcriptomes and Epitopes by Sequencing;checkpoint therapy;Clinic;Clinical;Clinical Data;Clinical Trials;comparative;Complement;Data;Data Commons;Data Set;Deposition;Disease;Disease remission;Drug Kinetics;Experimental Models;Failure;FDA approved;Genomics;Goals;Health;Health Care Costs;Human;Immune;Immune checkpoint inhibitor;Immune response;Immunobiology;Immunology;Immunotherapy;improved;Invaded;Literature;Malignant neoplasm of urinary bladder;Malignant Neoplasms;Medical Oncology;microbiome research;MicroRNAs;Minority;Mission;Modeling;Molecular;molecular subtypes;Nature;NCI Center for Cancer Research;Neoplasm Metastasis;neoplastic cell;Outcome;outcome prediction;Pathologic;Pathology;Patients;Persons;pre-clinical;Prediction of Response to Therapy;prevent;programmed cell death protein 1;Public Health;Publishing;Reporting;Research;response;RNA analysis;Safety;Sampling;single-cell RNA sequencing;success;transcriptome sequencing;Transitional Cell Carcinoma;treatment response;tumor;tumor microenvironment;TYRO3 gene;United States;United States National Institutes of Health;Universities;Work

PROJECT_TITLE: Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer